{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T13:17:35Z","timestamp":1771334255534,"version":"3.50.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,27]],"date-time":"2021-04-27T00:00:00Z","timestamp":1619481600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,4,27]],"date-time":"2021-04-27T00:00:00Z","timestamp":1619481600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP20fk0210072, JP20fk0210047"],"award-info":[{"award-number":["JP20fk0210072, JP20fk0210047"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>In patients with hepatitis C virus (HCV) and malignant lymphoma, hepatitis C flare during R-CHOP can result in discontinuation of treatment. However, appropriate therapeutic strategies for managing hepatitis C flare during R-CHOP have not been established, and this issue is complicated by conflicting results regarding the use of direct-acting antivirals in patients with uncontrolled malignancies.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Case presentation<\/jats:title>\n                <jats:p>We report the first case of effective and safe treatment with on-demand 8-week glecaprevir and pibrentasvir for hepatitis C flare during R-CHOP in a patient with diffuse large B-cell lymphoma (DLBCL). The patient completed five additional courses of R-CHOP without hepatic toxicity. A complete response of DLBCL and a sustained virological response were observed at 24\u2009weeks after glecaprevir and pibrentasvir completion.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>On-demand, direct-acting antivirals could be a novel strategy for managing hepatitis C flare during R-CHOP.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12879-021-06091-x","type":"journal-article","created":{"date-parts":[[2021,4,27]],"date-time":"2021-04-27T09:21:39Z","timestamp":1619515299000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Successful treatment by on-demand glecaprevir and pibrentasvir for hepatitis C flare during R-CHOP in patients with diffuse large B-cell lymphoma: a case report"],"prefix":"10.1186","volume":"21","author":[{"given":"Machiko","family":"Umemura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0098-9106","authenticated-orcid":false,"given":"Goki","family":"Suda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shihori","family":"Tsukamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ko","family":"Ebata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinjiro","family":"Takahash","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Sasaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sae","family":"Nakajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariko","family":"Ozasa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatoshi","family":"Takano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaki","family":"Katagiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoya","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,4,27]]},"reference":[{"issue":"3","key":"6091_CR1","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s12072-015-9684-3","volume":"10","author":"K Gill","year":"2016","unstructured":"Gill K, Ghazinian H, Manch R, Gish R. Hepatitis C virus as a systemic disease: reaching beyond the liver. Hepatol Int. 2016;10(3):415\u201323. https:\/\/doi.org\/10.1007\/s12072-015-9684-3.","journal-title":"Hepatol Int"},{"issue":"4","key":"6091_CR2","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1056\/NEJMoa1702417","volume":"378","author":"S Zeuzem","year":"2018","unstructured":"Zeuzem S, Foster GR, Wang S, Asatryan A, Gane E, Feld JJ, et al. Glecaprevir-Pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection. N Engl J Med. 2018;378(4):354\u201369. https:\/\/doi.org\/10.1056\/NEJMoa1702417.","journal-title":"N Engl J Med"},{"issue":"20","key":"6091_CR3","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1056\/NEJMoa1402355","volume":"370","author":"KV Kowdley","year":"2014","unstructured":"Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370(20):1879\u201388. https:\/\/doi.org\/10.1056\/NEJMoa1402355.","journal-title":"N Engl J Med"},{"issue":"1","key":"6091_CR4","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1007\/s00535-017-1353-y","volume":"53","author":"G Suda","year":"2018","unstructured":"Suda G, Furusyo N, Toyoda H, Kawakami Y, Ikeda H, Suzuki M, et al. Daclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection: a nationwide retrospective study in Japan. J Gastroenterol. 2018;53(1):119\u201328. https:\/\/doi.org\/10.1007\/s00535-017-1353-y.","journal-title":"J Gastroenterol"},{"issue":"4","key":"6091_CR5","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1053\/j.gastro.2019.01.271","volume":"157","author":"HA Torres","year":"2019","unstructured":"Torres HA, Pundhir P, Mallet V. Hepatitis C virus infection in patients with Cancer: impact on clinical trial enrollment, selection of therapy, and prognosis. Gastroenterology. 2019;157(4):909\u201316. https:\/\/doi.org\/10.1053\/j.gastro.2019.01.271.","journal-title":"Gastroenterology"},{"issue":"21","key":"6091_CR6","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1182\/blood-2016-05-714667","volume":"128","author":"L Arcaini","year":"2016","unstructured":"Arcaini L, Besson C, Frigeni M, Fontaine H, Goldaniga M, Casato M, et al. Interferon-free antiviral treatment in B-cell lymphoproliferative disorders associated with hepatitis C virus infection. Blood. 2016;128(21):2527\u201332. https:\/\/doi.org\/10.1182\/blood-2016-05-714667.","journal-title":"Blood"},{"issue":"5","key":"6091_CR7","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1038\/s41375-019-0687-2","volume":"34","author":"M Frigeni","year":"2020","unstructured":"Frigeni M, Besson C, Visco C, Fontaine H, Goldaniga M, Visentini M, et al. Interferon-free compared to interferon-based antiviral regimens as first-line therapy for B-cell lymphoproliferative disorders associated with hepatitis C virus infection. Leukemia. 2020;34(5):1462\u20136. https:\/\/doi.org\/10.1038\/s41375-019-0687-2.","journal-title":"Leukemia"},{"issue":"9","key":"6091_CR8","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1093\/annonc\/mdl131","volume":"17","author":"C Visco","year":"2006","unstructured":"Visco C, Arcaini L, Brusamolino E, Burcheri S, Ambrosetti A, Merli M, et al. Distinctive natural history in hepatitis C virus positive diffuse large B-cell lymphoma: analysis of 156 patients from northern Italy. Ann Oncol. 2006;17(9):1434\u201340. https:\/\/doi.org\/10.1093\/annonc\/mdl131.","journal-title":"Ann Oncol"},{"issue":"32","key":"6091_CR9","doi-asserted-by":"publisher","first-page":"11054","DOI":"10.3748\/wjg.v20.i32.11054","volume":"20","author":"C Visco","year":"2014","unstructured":"Visco C, Finotto S. Hepatitis C virus and diffuse large B-cell lymphoma: pathogenesis, behavior and treatment. World J Gastroenterol. 2014;20(32):11054\u201361. https:\/\/doi.org\/10.3748\/wjg.v20.i32.11054.","journal-title":"World J Gastroenterol"},{"issue":"3","key":"6091_CR10","doi-asserted-by":"publisher","first-page":"489","DOI":"10.3324\/haematol.2013.094318","volume":"99","author":"M Merli","year":"2014","unstructured":"Merli M, Visco C, Spina M, Luminari S, Ferretti VV, Gotti M, et al. Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana Linfomi. Haematologica. 2014;99(3):489\u201396. https:\/\/doi.org\/10.3324\/haematol.2013.094318.","journal-title":"Haematologica"},{"issue":"7","key":"6091_CR11","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1179\/1607845413Y.0000000147","volume":"19","author":"AH Zaky","year":"2014","unstructured":"Zaky AH, Bakry R, El-sayed MI, Elwanis MA, Nabih O. Impact of treatment-related toxicity on outcome of HCV-positive diffuse large B-cell lymphoma in rituximab era. Hematology. 2014;19(7):412\u20136. https:\/\/doi.org\/10.1179\/1607845413Y.0000000147.","journal-title":"Hematology"},{"issue":"9","key":"6091_CR12","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1080\/10428194.2020.1755859","volume":"61","author":"M Merli","year":"2020","unstructured":"Merli M, Defrancesco I, Visco C, Besson C, Di Rocco A, Arcari A, et al. Direct-acting antivirals in relapsed or refractory hepatitis C virus-associated diffuse large B-cell lymphoma. Leuk Lymphoma. 2020;61(9):2122\u20138. https:\/\/doi.org\/10.1080\/10428194.2020.1755859.","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"6091_CR13","doi-asserted-by":"publisher","first-page":"e720","DOI":"10.1634\/theoncologist.2018-0331","volume":"24","author":"M Merli","year":"2019","unstructured":"Merli M, Frigeni M, Alric L, Visco C, Besson C, Mannelli L, et al. Direct-acting antivirals in hepatitis C virus-associated diffuse large B-cell lymphomas. Oncologist. 2019;24(8):e720\u20139. https:\/\/doi.org\/10.1634\/theoncologist.2018-0331.","journal-title":"Oncologist"},{"issue":"1","key":"6091_CR14","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1002\/hep.29344","volume":"67","author":"HA Torres","year":"2018","unstructured":"Torres HA, Hosry J, Mahale P, Economides MP, Jiang Y, Lok AS. Hepatitis C virus reactivation in patients receiving cancer treatment: a prospective observational study. Hepatology. 2018;67(1):36\u201347. https:\/\/doi.org\/10.1002\/hep.29344.","journal-title":"Hepatology"},{"issue":"1","key":"6091_CR15","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/hep.29364","volume":"67","author":"M Persico","year":"2018","unstructured":"Persico M, Aglitti A, Caruso R, De Renzo A, Selleri C, Califano C, et al. Efficacy and safety of new direct antiviral agents in hepatitis C virus-infected patients with diffuse large B-cell non-Hodgkin's lymphoma. Hepatology. 2018;67(1):48\u201355. https:\/\/doi.org\/10.1002\/hep.29364.","journal-title":"Hepatology"},{"issue":"11","key":"6091_CR16","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1002\/ijc.30372","volume":"139","author":"J Hosry","year":"2016","unstructured":"Hosry J, Mahale P, Turturro F, Miranda RN, Economides MP, Granwehr BP, et al. Antiviral therapy improves overall survival in hepatitis C virus-infected patients who develop diffuse large B-cell lymphoma. Int J Cancer. 2016;139(11):2519\u201328. https:\/\/doi.org\/10.1002\/ijc.30372.","journal-title":"Int J Cancer"},{"issue":"4","key":"6091_CR17","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.bbmt.2015.12.010","volume":"22","author":"A Kyvernitakis","year":"2016","unstructured":"Kyvernitakis A, Mahale P, Popat UR, Jiang Y, Hosry J, Champlin RE, et al. Hepatitis C virus infection in patients undergoing hematopoietic cell transplantation in the era of direct-acting antiviral agents. Biol Blood Marrow Transplant. 2016;22(4):717\u201322. https:\/\/doi.org\/10.1016\/j.bbmt.2015.12.010.","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"6091_CR18","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1016\/j.virol.2010.06.020","volume":"405","author":"K Mishima","year":"2010","unstructured":"Mishima K, Sakamoto N, Sekine-Osajima Y, Nakagawa M, Itsui Y, Azuma S, et al. Cell culture and in vivo analyses of cytopathic hepatitis C virus mutants. Virology. 2010;405(2):361\u20139. https:\/\/doi.org\/10.1016\/j.virol.2010.06.020.","journal-title":"Virology"},{"issue":"3","key":"6091_CR19","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1128\/AAC.02264-15","volume":"60","author":"EJ Lawitz","year":"2015","unstructured":"Lawitz EJ, O'Riordan WD, Asatryan A, Freilich BL, Box TD, Overcash JS, et al. Potent antiviral activities of the direct-acting antivirals ABT-493 and ABT-530 with three-day Monotherapy for hepatitis C virus genotype 1 infection. Antimicrob Agents Chemother. 2015;60(3):1546\u201355. https:\/\/doi.org\/10.1128\/AAC.02264-15.","journal-title":"Antimicrob Agents Chemother"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-06091-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-021-06091-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-021-06091-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,27]],"date-time":"2021-04-27T09:27:41Z","timestamp":1619515661000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-021-06091-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,27]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["6091"],"URL":"https:\/\/doi.org\/10.1186\/s12879-021-06091-x","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,27]]},"assertion":[{"value":"18 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent to publish this case report was obtained from the patient.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Professor Naoya Sakamoto received research grants from Gilead Sciences Inc. and AbbVie Inc. Dr. Goki Suda received research grants from Bristol Myers Squibb and MSD K.K.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"389"}}